The most common adverse events reported for satralizumab in the SatraGO-1 and SatraGO-2 clinical trials were upper respiratory tract infections and elevated alanine aminotransferase levels

552c7ae14Space

Health

Health news, debates, and claims covering public health, mental health, nutrition, medical care, and health policy.

1 debate·6,984 claims·43 news stories

0